BIIB 059

Drug Profile

BIIB 059

Alternative Names: BIIB-059

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus

Most Recent Events

  • 11 Nov 2016 Interim pharmacodynamics data from a phase I trial in healthy volunteers presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 20 Oct 2016 Phase-II clinical trials in Systemic lupus erythematosus in Taiwan, South Korea, Bulgaria (IV) (NCT02847598) after October 2016
  • 20 Oct 2016 Phase-II clinical trials in Systemic lupus erythematosus in Taiwan, South Korea, Bulgaria (SC) (NCT02847598) after October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top